Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

The incorporation of rituximab into various regimens has improved depth of response in Waldenstrom macroglobulinaemia (WM), though the impact of achieving better responses remains to be determined. We examined response depth on progression-free survival (PFS) in 159 rituximab-naive WM patients who received rituximab-based therapy. The median follow-up was 33 5 months, and categorical responses were as follows: complete response (CR, 8.8%); very good partial response (VGPR, 13.2%); partial response (50%); minor response (18.9%); Non-Responders (8.8%). Sequencing for polymorphic variants of FCGR2A, FCGR2B, and FCGR3A was performed, and impact on response depth determined. Achievement of better categorical responses was incrementally associated with improved PFS (P < 0 0001). No separation was observed between CR and VGPR, and attainment of at least a VGPR was associated with improved time-to-progression. Neither age, serum IgM, haematocrit, platelet count, serum beta(2)microglobulin, WM International Prognostic Scoring System score, and treatment group predicted for CR/VGPR. Polymorphisms at FCGR3A-48 and -158 were associated with improved categorical responses, particularly attainment of CR/VGPR (P <= 0 03). The attainment of CR/VGPR was associated with significantly longer PFS in rituximab-naive WM patients undergoing rituximab-based therapy, and was predicted by polymorphisms in FCGR3A.